Nabriva Therapeutics Reports Positive Results from Phase II Trial of Pleuromutilin Antibiotic BC-3781 in ABSSSI

VIENNA--(BUSINESS WIRE)--Nabriva Therapeutics today announced the successful results of a Phase II clinical trial of BC-3781 in acute bacterial skin and skin structure infections (ABSSSI). Nabriva’s lead product BC-3781 is the first of a new class of systemically available pleuromutilin antibiotics for the treatment of serious skin infections and pneumonia. BC-3781 is being developed for both oral and intravenous formulations.